|
[1]
|
中国研究型医院学会精准医学与肿瘤MDT专业委员会. 中国胆道肿瘤多学科综合治疗专家共识[J]. 肿瘤综合治疗电子杂志, 2023, 9(3): 57-68.
|
|
[2]
|
Wheatley, R.C., Kilgour, E., Jacobs, T., Lamarca, A., Hubner, R.A., Valle, J.W., et al. (2021) Potential Influence of the Microbiome Environment in Patients with Biliary Tract Cancer and Implications for Therapy. British Journal of Cancer, 126, 693-705. [Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
Mima, K., Nakagawa, S., Sawayama, H., Ishimoto, T., Imai, K., Iwatsuki, M., et al. (2017) The Microbiome and Hepatobiliary-Pancreatic Cancers. Cancer Letters, 402, 9-15. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Ganesan, P. and Kulik, L.M. (2023) Hepatocellular Carcinoma. Clinics in Liver Disease, 27, 85-102. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Gilles, H., Garbutt, T. and Landrum, J. (2022) Hepatocellular Carcinoma. Critical Care Nursing Clinics of North America, 34, 289-301. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Galle, P.R., Dufour, J., Peck-Radosavljevic, M., Trojan, J. and Vogel, A. (2020) Systemic Therapy of Advanced Hepatocellular Carcinoma. Future Oncology, 17, 1237-1251. [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Bangaru, S., Marrero, J.A. and Singal, A.G. (2019) Review Article: New Therapeutic Interventions for Advanced Hepatocellular Carcinoma. Alimentary Pharmacology & Therapeutics, 51, 78-89. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Sturm, N., Schuhbaur, J.S., Hüttner, F., Perkhofer, L. and Ettrich, T.J. (2022) Gallbladder Cancer: Current Multimodality Treatment Concepts and Future Directions. Cancers, 14, Article 5580. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
Roa, J.C., García, P., Kapoor, V.K., Maithel, S.K., Javle, M. and Koshiol, J. (2022) Gallbladder Cancer. Nature Reviews Disease Primers, 8, Article No. 69. [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
Ho, J., Fiocco, C. and Spencer, K. (2022) Treating Biliary Tract Cancers: New Targets and Therapies. Drugs, 82, 1629-1647. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Moris, D., Palta, M., Kim, C., Allen, P.J., Morse, M.A. and Lidsky, M.E. (2023) Advances in the Treatment of Intrahepatic Cholangiocarcinoma: An Overview of the Current and Future Therapeutic Landscape for Clinicians. CA: A Cancer Journal for Clinicians, 73, 198-222. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
Zhou, Y., Ran, X. and Han, M. (2024) BCLAF1 Is Expressed as a Potential Anti-Oncogene in Bile Duct Cancer. Biochemical Genetics. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Yi, M., Zheng, X., Niu, M., Zhu, S., Ge, H. and Wu, K. (2022) Combination Strategies with PD-1/PD-L1 Blockade: Current Advances and Future Directions. Molecular Cancer, 21, Article No. 28. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Heintz-Buschart, A. and Wilmes, P. (2018) Human Gut Microbiome: Function Matters. Trends in Microbiology, 26, 563-574. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Kuziel, G.A. and Rakoff-Nahoum, S. (2022) The Gut Microbiome. Current Biology, 32, R257-R264. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
Sidhu, M. and van der Poorten, D. (2017) The Gut Microbiome. Australian Family Physician, 46, 206-211.
|
|
[17]
|
Schmidt, T.S.B., Raes, J. and Bork, P. (2018) The Human Gut Microbiome: From Association to Modulation. Cell, 172, 1198-1215. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
Rao, B., Ren, T., Wang, X., Wang, H., Zou, Y., Sun, Y., et al. (2021) Dysbiosis in the Human Microbiome of Cholangiocarcinoma. Frontiers in Physiology, 12, Article 715536. [Google Scholar] [CrossRef] [PubMed]
|
|
[19]
|
Liu, S., Li, W., Chen, J., Li, M., Geng, Y., Liu, Y., et al. (2024) The Footprint of Gut Microbiota in Gallbladder Cancer: A Mechanistic Review. Frontiers in Cellular and Infection Microbiology, 14, Article 1374238. [Google Scholar] [CrossRef] [PubMed]
|
|
[20]
|
Chung, I.Y., Kim, J. and Koh, A. (2024) The Microbiome Matters: Its Impact on Cancer Development and Therapeutic Responses. Journal of Microbiology, 62, 137-152. [Google Scholar] [CrossRef] [PubMed]
|
|
[21]
|
Ervin, S.M., Ramanan, S.V. and Bhatt, A.P. (2020) Relationship between the Gut Microbiome and Systemic Chemotherapy. Digestive Diseases and Sciences, 65, 874-884. [Google Scholar] [CrossRef] [PubMed]
|
|
[22]
|
Zwielehner, J., Lassl, C., Hippe, B., Pointner, A., Switzeny, O.J., Remely, M., et al. (2011) Changes in Human Fecal Microbiota Due to Chemotherapy Analyzed by TaqMan-PCR, 454 Sequencing and PCR-DGGE Fingerprinting. PLOS ONE, 6, e28654. [Google Scholar] [CrossRef] [PubMed]
|
|
[23]
|
Mitra, A., Grossman Biegert, G.W., Delgado, A.Y., Karpinets, T.V., Solley, T.N., Mezzari, M.P., et al. (2020) Microbial Diversity and Composition Is Associated with Patient-Reported Toxicity during Chemoradiation Therapy for Cervical Cancer. International Journal of Radiation Oncology Biology Physics, 107, 163-171. [Google Scholar] [CrossRef] [PubMed]
|
|
[24]
|
Shi, W., Shen, L., Zou, W., Wang, J., Yang, J., Wang, Y., et al. (2020) The Gut Microbiome Is Associated with Therapeutic Responses and Toxicities of Neoadjuvant Chemoradiotherapy in Rectal Cancer Patients—A Pilot Study. Frontiers in Cellular and Infection Microbiology, 10, Article 562463. [Google Scholar] [CrossRef] [PubMed]
|
|
[25]
|
Amit, U., Facciabene, A. and Ben-Josef, E. (2023) Radiation Therapy and the Microbiome; More than a Gut Feeling. The Cancer Journal, 29, 84-88. [Google Scholar] [CrossRef] [PubMed]
|
|
[26]
|
Jian, Y., Zhang, D., Liu, M., Wang, Y. and Xu, Z. (2021) The Impact of Gut Microbiota on Radiation-Induced Enteritis. Frontiers in Cellular and Infection Microbiology, 11, Article 586392. [Google Scholar] [CrossRef] [PubMed]
|
|
[27]
|
Pant, K., Venugopal, S.K., Lorenzo Pisarello, M.J. and Gradilone, S.A. (2023) The Role of Gut Microbiome-Derived Short-Chain Fatty Acid Butyrate in Hepatobiliary Diseases. The American Journal of Pathology, 193, 1455-1467. [Google Scholar] [CrossRef] [PubMed]
|
|
[28]
|
Mirzaei, R., Afaghi, A., Babakhani, S., Sohrabi, M.R., Hosseini-Fard, S.R., Babolhavaeji, K., et al. (2021) Role of Microbiota-Derived Short-Chain Fatty Acids in Cancer Development and Prevention. Biomedicine & Pharmacotherapy, 139, Article ID: 111619. [Google Scholar] [CrossRef] [PubMed]
|
|
[29]
|
Son, M. and Cho, H. (2023) Anticancer Effects of Gut Microbiota-Derived Short-Chain Fatty Acids in Cancers. Journal of Microbiology and Biotechnology, 33, 849-856. [Google Scholar] [CrossRef] [PubMed]
|
|
[30]
|
Duan, H., Wang, L., Huangfu, M. and Li, H. (2023) The Impact of Microbiota-Derived Short-Chain Fatty Acids on Macrophage Activities in Disease: Mechanisms and Therapeutic Potentials. Biomedicine & Pharmacotherapy, 165, Article ID: 115276. [Google Scholar] [CrossRef] [PubMed]
|
|
[31]
|
Yao, Y., Cai, X., Fei, W., Ye, Y., Zhao, M. and Zheng, C. (2020) The Role of Short-Chain Fatty Acids in Immunity, Inflammation and Metabolism. Critical Reviews in Food Science and Nutrition, 62, 1-12. [Google Scholar] [CrossRef] [PubMed]
|
|
[32]
|
Rossi, T., Vergara, D., Fanini, F., Maffia, M., Bravaccini, S. and Pirini, F. (2020) Microbiota-Derived Metabolites in Tumor Progression and Metastasis. International Journal of Molecular Sciences, 21, Article 5786. [Google Scholar] [CrossRef] [PubMed]
|
|
[33]
|
Cao, W., Yu, P., Yang, K. and Cao, D. (2022) Aflatoxin B1: Metabolism, Toxicology, and Its Involvement in Oxidative Stress and Cancer Development. Toxicology Mechanisms and Methods, 32, 395-419. [Google Scholar] [CrossRef] [PubMed]
|
|
[34]
|
Gariépy, J. (2001) The Use of Shiga-Like Toxin 1 in Cancer Therapy. Critical Reviews in Oncology/Hematology, 39, 99-106. [Google Scholar] [CrossRef] [PubMed]
|
|
[35]
|
Han, J., Zhang, B., Zhang, Y., Yin, T., Cui, Y., Liu, J., et al. (2023) Gut Microbiome: Decision-Makers in the Microenvironment of Colorectal Cancer. Frontiers in Cellular and Infection Microbiology, 13, Article 1299977. [Google Scholar] [CrossRef] [PubMed]
|
|
[36]
|
González-Sánchez, P. and DeNicola, G.M. (2021) The Microbiome(s) and Cancer: Know Thy Neighbor(s). The Journal of Pathology, 254, 332-343. [Google Scholar] [CrossRef] [PubMed]
|
|
[37]
|
Höfs, S., Mogavero, S. and Hube, B. (2016) Interaction of Candida Albicans with Host Cells: Virulence Factors, Host Defense, Escape Strategies, and the Microbiota. Journal of Microbiology, 54, 149-169. [Google Scholar] [CrossRef] [PubMed]
|
|
[38]
|
Sevcikova, A., Mladosievicova, B., Mego, M. and Ciernikova, S. (2023) Exploring the Role of the Gut and Intratumoral Microbiomes in Tumor Progression and Metastasis. International Journal of Molecular Sciences, 24, Article 17199. [Google Scholar] [CrossRef] [PubMed]
|
|
[39]
|
Lopez, L.R., Bleich, R.M. and Arthur, J.C. (2021) Microbiota Effects on Carcinogenesis: Initiation, Promotion, and Progression. Annual Review of Medicine, 72, 243-261. [Google Scholar] [CrossRef] [PubMed]
|
|
[40]
|
Gopalakrishnan, V., Helmink, B.A., Spencer, C.N., Reuben, A. and Wargo, J.A. (2018) The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy. Cancer Cell, 33, 570-580. [Google Scholar] [CrossRef] [PubMed]
|
|
[41]
|
Sharma, P.C., Sharma, D., Sharma, A., Bhagat, M., Ola, M., Thakur, V.K., et al. (2022) Recent Advances in Microbial Toxin-Related Strategies to Combat Cancer. Seminars in Cancer Biology, 86, 753-768. [Google Scholar] [CrossRef] [PubMed]
|
|
[42]
|
Vétizou, M., Pitt, J.M., Daillère, R., Lepage, P., Waldschmitt, N., Flament, C., et al. (2015) Anticancer Immunotherapy by CTLA-4 Blockade Relies on the Gut Microbiota. Science, 350, 1079-1084. [Google Scholar] [CrossRef] [PubMed]
|
|
[43]
|
Wang, J., Kuo, C., Kuo, F., Wang, Y., Hsu, W., Yu, F., et al. (2019) Fecal Microbiota Transplantation: Review and Update. Journal of the Formosan Medical Association, 118, S23-S31. [Google Scholar] [CrossRef] [PubMed]
|
|
[44]
|
Chen, Z., Xie, H., Hu, M., et al. (2020) Recent Progress in Treatment of Hepatocellular Carcinoma. American Journal of Cancer Research, 10, 2993-3036.
|